Inflammatory Bowel Disease Research Review, Issue 82

In this issue:

Mechanisms and management of loss of response to anti-TNF therapy in CD
Rare and severe adverse events in paediatric IBD
Early anti-TNF therapy in children with newly diagnosed CD
First-line infliximab biosimilar vs. conventional treatment in paediatric CD
UPF, disease activity and inflammation in UC
High BMI affects anti-TNF therapy response in paediatric CD
Early-life tobacco smoke exposure and later IBD risk
SC infliximab concentrations and remission in IBD
Baseline corticosteroids and upadacitinib’s efficacy and safety in UC
Ontamalimab for moderate-to-severe UC or CD